Grima used two mouse models of Huntington's disease: one with a human version of the mutant Huntingtin protein and
another with an aggressive form of the disease that contains only the first portion of the mouse Huntingtin protein.
For years, scientists have observed that tumor cells from certain breast cancer patients
with aggressive forms of the disease contained low levels of mitochondrial DNA.
Not exact matches
Women
with the variant were at much higher risk for cancer, had more recurrences, were often hit
with multiple cancers and were more likely to die from
aggressive forms of these
diseases.
The study evaluated 56 patients
with ovarian clear cell adenocarcinoma (CCA), an
aggressive form of ovarian cancer that is more likely to be resistant to chemotherapy and to have a poorer prognosis than other
forms of this
disease.
Women
with particularly
aggressive forms of breast cancer could be identified by a test that predicts whether the
disease is likely to spread to the brain.
When the investigators analyzed the genes
of MECs infected
with EBV, they found genetic characteristics associated
with high - grade, estrogen - receptor - negative breast cancer (an
aggressive form of the
disease).
Additionally, a
form of indolent B cell lymphoma, which progresses slowly
with only mild symptoms, can transform without warning into an
aggressive form of the
disease.
Men
with BRCA1 / 2 mutations who develop prostate cancer tend to develop these cancers at an earlier age than average and may develop more
aggressive forms of the
disease.
They found that when an MS - like
disease was induced in mice genetically engineered to be deficient in Tob1, the mice had significantly earlier onset compared
with wild - type mice, and developed a more
aggressive form of the
disease.
Low Cholesterol May Shrink Risk for High - Grade Prostate Cancer Men
with lower cholesterol are less likely than those
with higher levels to develop high - grade prostate cancer, an
aggressive form of the
disease with a poorer prognosis, according to results
of a Johns Hopkins collaborative study.
BUFFALO, N.Y. — Although men
with prostate cancer usually respond to standard treatment
with hormone therapy or chemotherapy, many will eventually experience progression or recurrence despite treatment — particularly those
with high - risk or
aggressive forms of the
disease.
While men
with the more
aggressive form of the cancer make up about 5 %
of the 180,000 to 200,000 cases
of prostate cancer in the U.S. each year, and only 12 % will have these mutations, that population is still at considerably higher risk
of developing advanced
disease.
Fortunately, many people
with bladder cancer have a less
aggressive form of the
disease (lower grade, superficial bladder cancer) that is usually not life threatening.